Air Medical Administration of Tranexamic Acid.
Journal of trauma nursing · 2016-12-30 · Other / unclear
Abstract
Traumatic injury is a significant cause of morbidity and mortality in the United States. Massive hemorrhage is responsible for the vast majority of deaths. Evolution in trauma treatment has resulted in major improvements to emergency care. Tranexamic acid (TXA), an antifibrinolytic agent, is synthetically derived from amino acids. The CRASH-2 study demonstrated that the early administration of TXA results in significant decreases in morbidity and mortality. Experiences by coalition forces in Southwest Asia found a substantial increase in survival of trauma patients with early TXA administration. The PAMPer trial has demonstrated the success of taking plasma to the scene of the incident by helicopter; TXA offers additional benefits when transported by the same means. Air medical utilization of TXA can take battlefield trauma care to the scene of civilian traumatic injuries and save lives.
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Helicopter & air ambulance · Haemostatics · Military & tactical · Tranexamic acid
Related articles
- Early experience with transfusing low titer group O whole blood in the pre-hospital setting in Israel. (Transfusion, 2020)
- Factors that influence the administration of tranexamic acid (TXA) to trauma patients in prehospital settings: a systematic review. (BMJ Open, 2023)
- Efficacy and Safety of Tranexamic Acid in Emergency Trauma: A Systematic Review and Meta-Analysis. (J Clin Med, 2021)
- Intramuscular Tranexamic Acid in Tactical and Combat Settings. (J Spec Oper Med, 2018)
- Sterility of Tranexamic Acid Syringes Prefilled by Tactical Combat Medics in a Garrison Setting. (J Spec Oper Med, 2026)
- Local delivery of tranexamic acid for hemorrhage control in trauma: a narrative review. (Front Drug Deliv, 2026)